5fu - OmicsDI

Show results for

Unknown (322)
Clinical (86)
Genomics (85)
Transcriptomics (70)
Proteomics (19)
Metabolomics (4)
Other (2)

Organisms

Homo sapiens (78)
Mus musculus (12)
Lactococcus lactis subsp. lactis bv. diacetylactis (7)
Chlorella sorokiniana (7)
Streptococcus pyogenes MGAS315 (7)
Onygena corvina (7)
Aspidimorpha (7)
Chelymorpha gressoria (7)
Cassida rubiginosa (7)
Charidotella sexpunctata (7)
Acromis sparsa (7)
NEWT:502779 (7)
Mycobacteroides abscessus ATCC 19977 (7)
Blumea (7)
Cancer irroratus (7)
NEWT:1933298 (7)
Chlamydia pneumoniae (7)
Shigella flexneri 5a (7)
Escherichia phage vB_EcoP_SU10 (7)
Klebsiella sp. RCJ4 (7)
Serratia sp. RJAL6 (7)
Leptospira interrogans serovar Manilae (7)
Ochrogaster lunifer (7)
Clostridioides difficile str. A-027 (7)
Enterobacter sp. 198 (7)
Schizosaccharomyces pombe (2)
Pan troglodytes (1)
Candida albicans (1)
Drosophila melanogaster (1)
Rattus norvegicus (1)

Organisms

Homo sapiens (38)
Mus musculus (11)
Schizosaccharomyces pombe (1)
Rattus norvegicus (1)

Repository

ENA (71)
biostudies-arrayexpress (49)
geo (30)
EGA (7)
jPOST (7)
pride (7)
MassIVE (3)
MetaboLights (3)
iProX (2)
MetabolomicsWorkbench (1)

Tissue

Cell culture (3)
Blood (1)
Pancreatic duct (1)
Anal canal (1)
Malignant cell (1)
Bone marrow (1)
Stem cell (1)
Blood cell (1)
Colon (1)

Disease

Colorectal Neoplasms (37)
Colorectal cancer (5)
Metastatic colorectal cancer (4)
Metastatic Colorectal Cancer (3)
Colorectal cancer (3)
Neoplasms (3)
Advanced/recurrent colorectal cancer (2)
Colorectal Cancer (2)
Locally advanced rectal cancer (1)
Colorectal cancer liver metastases (CRLM) (1)
Metastatic colon cancer (1)
Colon neoplasm (1)
Colonic neoplasms malignant (1)
Unresectable advanced colorectal cancer (1)
Metastatic colorectal cancer beyond progression on Fruquintinib monotherapy (1)
Locally advanced rectal cancer treated with pre-operative long course chemo-radiation and surgery (1)
RAS-wild type colorectal cancer (1)
Patients with histologically confirmed metastatic colorectal cancer (1)
Advanced and/or recurrent colorectal cancer (1)
Patients with the diagnosis of Stage II Colon cancer (1)
Liver metastases from colorectal cancer (1)
Cancer-Bowel-Back passage (rectum) or large bowel (colon) (1)
Anal canal cancer (1)
5-Fluorouracil toxicity (1)
Unresectable advanced/recurrent small intestinal cancer (1)
Breast Cancer (1)
Rectal cancer (1)
Metastatic colorectal cancer isolated in the liver (1)
Colorectal Cancer (1)
Anal Cancer (1)

Technology Type

Mass Spectrometry (8)
Mass spectrometry (3)
Shotgun proteomics (3)
Illumina HumanExome Array (1)
ESI (1)
All-ion fragmentation (1)
Data-independent acquisition (1)
Top-down proteomics (1)
Affinity purification coupled with mass spectrometry proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (3)
Illumina HiSeq 2500 (2)
NextSeq 500 (2)
Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - negative - reverse phase (2)
TBS380 (1)
Nanodrop2000 (1)
NA (1)
NextSeq 2000 (1)
BGISEQ-500 (1)
Illumina MiSeq (1)
Illumina HiSeq 2000 (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
LTQ Orbitrap (1)
Orbitrap Fusion Lumos (1)
Liquid Chromatography MS - positive - hilic (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2014 (11)
2024 (9)
2011 (9)
2025 (8)
2021 (8)
2013 (8)
2022 (7)
2016 (7)
2023 (5)
2020 (5)
2015 (4)
2012 (4)
2010 (2)
2008 (2)
2017 (2)
2004 (2)
2026 (1)
2009 (1)
2007 (1)
2006 (1)
2018 (1)

CHEBI ID

CHEBI:57429 (1)
CHEBI:80961 (1)
CHEBI:142699 (1)
CHEBI:77462 (1)
CHEBI:136579 (1)
CHEBI:132957 (1)
CHEBI:58115 (1)
CHEBI:137597 (1)
CHEBI:132676 (1)
CHEBI:132673 (1)
CHEBI:136186 (1)
CHEBI:60377 (1)
CHEBI:136239 (1)
CHEBI:140362 (1)
CHEBI:141590 (1)
CHEBI:141589 (1)
CHEBI:136259 (1)
CHEBI:136256 (1)
CHEBI:28664 (1)
CHEBI:67077 (1)
CHEBI:85568 (1)
CHEBI:85566 (1)
CHEBI:66858 (1)
CHEBI:74473 (1)
CHEBI:136203 (1)
CHEBI:72347 (1)
CHEBI:134428 (1)
CHEBI:134451 (1)
CHEBI:65294 (1)
CHEBI:72535 (1)

Metabolite Name

UTP_C13 (1)
FUTP (1)
5FUMP (1)
FdUMP (1)
FUrd (1)
5FU (1)
Citric acid-1,5-13C2 (1)
(2S,3R)-3-hydroxybutane-1,2,3-tricarboxylate (1)
Floxuridine (1)
SM 42:3 (1)
SM 42:2 (1)
SM 42:1 (1)
SM 36:2 (1)
SM 34:2 (1)
SM 34:1 (1)
PE P-38:4 B (1)
PE P-38:4 A (1)
PC O-36:4 (1)
PC O-30:1 (1)
PC 38:6 B (1)
PC 38:6 A (1)
PC 38:5 B (1)
PC 38:5 A (1)
PC 38:4 B (1)
PC 38:4 A (1)
PC 38:3 B (1)
PC 38:3 A (1)
PC 36:4 B (1)
PC 36:4 A (1)
Cer d18:1/16:0 (1)

First Public Date

2026 (13)
2014 (12)
2022 (11)
2024 (10)
2023 (5)
2020 (5)
2017 (5)
2021 (3)
2018 (3)
2025 (1)
2016 (1)
2015 (1)
2013 (1)

Study status

Completed (48)
Terminated (10)
Recruiting (10)
Active, not recruiting (8)
Ongoing (3)
Withdrawn (3)
Not provided (3)
Not yet recruiting (1)

Study type

Interventional (79)
Transcription profiling by array (30)
RNA-seq of coding RNA (8)
Observational (7)
RNA-seq of coding RNA from single cells (2)
Unknown experiment type (1)
Cell line - High-throughput sequencing (1)
Transcription profiling by tiling array (1)
Transcription profiling by RT-PCR (1)
Comparative genomic hybridization by array (1)
Other (1)
ChIP-seq (1)
DNA-seq (1)
RNA-seq of total RNA (1)

Release Date

2022 (64)
2024 (41)
2021 (31)
2023 (30)
2020 (26)
2015 (24)
2025 (21)
2016 (20)
2019 (19)
2018 (18)
2014 (17)
2013 (14)
2017 (12)
2011 (9)
2026 (5)
2010 (5)
2012 (4)
2009 (3)
2008 (3)
2007 (2)
2006 (1)
2004 (1)
2003 (1)

Lab affiliation

Université libre de Buxelles (ULB), Laboratory of Stem Cells and Cancer, 808 route de Lennik, 1070 Brussels, Belgium ; WELBIO, Université Libre de Bruxelles (ULB), 1070 Bruxelles, Belgium (2)
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, P. R. China. (1)
Molecular Oncology and Pathology Lab, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain (1)
Institute of Diagnostic and Interventional Radiology, Jena University Hospital – Friedrich Schiller Uni-versity Jena, Am Klinikum 1, D-07740 Jena, Germany (1)
Proteomics Biomedicum Core Facility, Div. of Chemistry I, Dept. Biochemistry & Biophysics, Karolinska Institutet, Stockholm, Sweden (1)
Albert Einstein College of Medicine (1)

Location

Japan (21)
United States (15)
Australia (13)
Italy (10)
France (9)
Spain (7)
Greece (5)
United Kingdom (5)
China (4)
Germany (4)
Belgium (4)
Canada (4)
Netherlands (4)
New Zealand (3)
Chile (3)
Denmark (3)
Sweden (3)
South Korea (3)
Poland (3)
Argentina (3)
Brazil (3)
Austria (3)
South Africa (2)
Norway (2)
Ukraine (2)
Romania (2)
Turkey (2)
Russia (2)
Czechia (2)
Hungary (2)

Keyword

Irinotecan (22)
Fluorouracil (21)
Leucovorin (20)
Oxaliplatin (18)
Levoleucovorin (11)
Bevacizumab (9)
Cetuximab (8)
Capecitabine (7)
5FU (5)
Folic Acid (5)
Panitumumab (5)
Aflibercept (4)
Liver metastasis (3)
FOLFIRI (3)
Metastatic colorectal cancer (3)
Genotyping (2)
Chemoembolization (2)
Oxaliplatino (2)
5-FU (2)
Gemcitabine (2)
FOLFOX (2)
Sorafenib (2)
Temozolomide (2)
Colorectal (2)
Metastatic (2)
Recurrent colon cancer (2)
Stage IV colon cancer (2)
Recurrent rectal cancer (2)
Stage IV rectal cancer (2)
Stage III rectal cancer (2)

Previous page
1 / 59
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 59
Next page

Sort by:

Relevance

Page size

Transcriptional response of Schizosaccharomyces pombe to 5-Fluorouracil (5FU)

We use high-density tiling DNA microarray technology to obtain the specific transcriptome-wide response induced by 5-Fluorouracil (5FU) in the eukaryotic model Schizosaccharomyces pombe. Schizosaccharomyces pombe cultures with 5FU added to a final concentration of 500 M-NM-

ORGANISM(S): Schizosaccharomyces pombe

2013-11-14 | E-GEOD-46919 | biostudies-arrayexpress

5-fluorouracil (5-Fu) resistant Bel/5Fu cell line and its parent Bel7402 cell line

The extensive drug resistance of hepatocellular carcinoma (HCC) has become the main cause of chemotherapy failure. The mechanisms leading to drug resistance in tumor cells are not well understood. Previous studies demonstrated that plasma membrane proteins play important roles in mediating drug disp...

ORGANISM(S): Homo Sapiens

PXD015917 |

Transcriptional response of Schizosaccharomyces pombe to 5-Fluorouracil (5FU)

We use high-density tiling DNA microarray technology to obtain the specific transcriptome-wide response induced by 5-Fluorouracil (5FU) in the eukaryotic model Schizosaccharomyces pombe.

ORGANISM(S): Schizosaccharomyces pombe

2013-11-14 | GSE46919 | GEO

Mouse HSC proteomics in basal or 5FU activated conditions

Proteomics of hemaopoietic stem cells under basal or 5FU activated conditions

ORGANISM(S): Mus musculus (Mouse)

2022-02-16 | PXD021340 | Pride